Stocktoria
Rallybio Corp RLYB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-29
Chart by TradingView
3/9
Piotroski F — financial health
0.76
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $858,000 | $636,000 | — | — | — |
| Operating income | -$33.1M | -$60.5M | -$78.9M | -$67.9M | -$45.6M |
| Net income | -$9.0M | -$57.8M | -$74.6M | -$66.7M | -$47.0M |
| Operating cash flow | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.5M |
| Free cash flow | — | -$49.3M | -$60.3M | -$57.3M | -$45.9M |
| Total assets | $62.3M | $68.1M | $115.6M | $180.4M | $182.2M |
| Total liabilities | $4.3M | $6.5M | $9.4M | $11.1M | $6.6M |
| Shareholders' equity | $58.0M | $61.7M | $106.2M | $169.3M | $175.6M |
| Ratios | |||||
| Operating margin | -3853.6% | -9511.9% | — | — | — |
| Net margin | -1046.4% | -9084.1% | — | — | — |
| FCF margin | — | -7748.7% | — | — | — |
| Return on assets | -14.4% | -84.8% | -64.5% | -36.9% | -25.8% |
| Return on equity | -15.5% | -93.7% | -70.2% | -39.4% | -26.8% |
| Current ratio | 14.50 | 10.87 | 12.39 | 16.71 | 27.61 |
| Revenue growth | 34.9% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 156,527 | $1.4M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.76 (distress)
- Working capital / assets 0.916
- Retained earnings / assets -4.851
- EBIT / assets -0.531
- Equity / liabilities 13.462
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001739410 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.